Pricing Log in Create free account
Friday 6 November 2026 Export QGEN’s income statement to Excel — free account

QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.

Revenue
+0.28%
EPS
+7.94%
Free cash flow
+30.5%
Total debt
+13.8%

Quarter to June 2026, against a year earlier

50.46 0.40 −0.79%
Market cap
$10.5B
P/E
26.1×
Fwd P/E
26.0×
Dividend yield
0.69%
F-score
8/9
Altman Z
3.94
Beneish M
−2.60
Dividend safety
66/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.53%

Capital & Financial Ratios $m

Size
Market Cap 10,500.00
Revenue ttm 2,100.36
Net income ttm 409.32
Free cash flow ttm 440.60
Net debt Q 850.12
Valuation
P/E 26.07
Forward P/E 26.00
Price / sales 5.00
Forward P/S Powerpack
Price / FCF 23.83
Price / book 3.13
Financial health
Current ratio Q 2.85 (at or above 1.5: strong)
Debt / equity Q 0.49 (at or below 0.5: strong)
Interest coverage Q 13.21
Growth
Revenue growth Q +0.28% (above 0%: growing)
Operating income growth Q +8.61% (above 0%: growing)
EPS, this year +2.06%
EPS, next year A +7.60%
Revenue, next year A +2.20%
EPS, past 5 yrs +2.58%
EPS, next 5 yrs A +6.30%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.4×, against a ten-year median of 5.6×; over the ten years it ranged from 4.1× in 2026 to 7.7× in 2020.
P/E against its own 10 years 27.94%
10-year low 10-year high
P/S against its own 10 years 35.42%
10-year low 10-year high
P/B against its own 10 years 59.26%
10-year low 10-year high
EV/Sales against its own 10 years 40.12%
10-year low 10-year high
EV/FCF against its own 10 years 29.19%
10-year low 10-year high

Dividends

Yield
0.69%
Annual rate
0.35
Payout ratio
17.9%
Growth, 2024–25
+18.7%/yr
  1. 1.37 ’24
  2. 1.63 ’25 +19
  3. 0.11 ’26e −93
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,058 1,153 1,099 794
Receivables 382 349 403 390
Inventory 398 279 302 311
Other — — — —
2,148 1,960 1,995 1,657
2023 2024 2025 Q'26
Payables 84 83 73 79
ST’ Debt 588 552 — 17
Other — — — —
1,079 1,042 512 581

Compound Annual Growth %

10y 5y 3y
Sales 5.02% 2.25% (0.81%)
Cash Flow 7.50% 7.40% (2.92%)
Earnings 12.56% 3.42% 0.13%
Book Value 3.94% 6.19% 2.91%

Earnings Trends EPS, adjusted, against the consensus

Sep 2026 Estimate 0.63 Actual 0.65

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Dec 2025 0.61 0.62 Beat by 0.01
Mar 2026 0.55 0.54 Miss by 0.01
Jun 2026 0.60 0.62 Beat by 0.02
Sep 2026 0.63 0.65 Beat by 0.02
Dec 2026 0.65 — Reports 3 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.33 0.50 — — —
’25 0.43 0.46 0.63 0.49 1.94
’24 0.39 (0.90) 0.48 0.41 0.37
’23 0.41 0.39 0.38 0.45 1.48
’22 0.75 0.47 0.40 0.44 2.05
’21 0.63 0.58 0.64 0.63 2.47
’20 0.19 0.42 0.08 1.02 1.71
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 492 535 — — —
’25 483 534 533 540 2,090
’24 459 496 502 521 1,978
’23 485 495 476 509 1,965
’22 628 516 500 498 2,142
’21 567 567 535 582 2,252
’20 372 443 484 571 1,870
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 101 201 — — —
’25 140 161 165 188 654
’24 133 167 182 192 674
’23 72 111 125 151 459
’22 207 172 212 124 715
’21 129 156 156 198 639
’20 16 135 37 270 458
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 52 157 — — —
’25 95 121 115 117 447
’24 95 128 138 142 502
’23 34 80 84 99 297
’22 169 134 185 78 566
’21 74 110 104 144 432
’20 (12) 13 (50) 203 154
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1,338 1,418 1,502 1,526 1,870 2,252 2,142 1,965 1,978 2,090 2,100 +5.1% 2,136 2,243 2,374 +4.3%
Gross margin, % 63.13 65.08 66.65 65.86 65.91 64.43 64.65 62.77 48.90 62.18 62.20 (0.9) pt
EBT 57 114 226 (78) 439 626 513 430 121 490 462 +27.0%
EBT margin, % 4.25 8.07 15.03 (5.10) 23.50 27.79 23.94 21.87 6.12 23.46 21.99 +19.2 pt
Net income 80 40 190 (41) 359 513 423 341 84 425 409 +20.3%
Per share, $
Per share, $ Revenue 6.36 6.94 7.40 7.51 9.14 11.02 10.19 9.07 8.89 9.62 10.18 +4.7%
Earnings 0.38 0.19 0.92 (0.20) 1.71 2.47 2.05 1.60 0.39 1.94 1.95 +19.9%
Cash flow 1.62 1.40 1.77 1.63 2.24 3.13 3.40 2.12 3.03 3.01 3.17 +7.1%
Capex (0.45) (0.61) (0.74) (1.35) (1.49) (1.01) (0.71) (0.75) (0.77) (0.95) (1.04) +8.8%
Free cash flow 1.18 0.79 1.03 0.28 0.75 2.12 2.69 1.37 2.26 2.06 2.14 +6.4%
Book value 12.39 12.44 12.98 12.49 13.67 15.16 16.49 17.57 16.02 17.39 16.27 +3.8%
Shares, m 210 204 203 203 205 204 210 217 223 217 209 +0.4%
Valuation, ×
Valuation, × P/E 79.51 184.40 42.01 0.00 34.54 25.15 27.14 29.74 127.54 23.48 26.07 57.4
P/S 4.76 5.05 5.20 5.02 6.45 5.63 5.47 5.37 5.43 4.92 5.00 5.3
P/B 2.44 2.81 2.96 3.02 4.31 4.09 3.38 2.77 3.01 2.72 3.13 3.2
EV/Sales 5.16 5.56 5.65 5.57 7.10 6.02 5.68 5.60 5.55 5.43 5.40 5.7
EV/FCF 27.86 48.55 40.65 151.99 86.47 31.33 21.48 37.12 21.84 25.35 25.76 49.3
Cash, $m
Cash, $m Operating cash flow 342 287 359 331 458 639 715 459 674 654 654 +7.5%
Capex (94) (124) (151) (275) (304) (207) (149) (163) (171) (207) (214) +9.2%
Free cash flow 248 162 209 56 154 432 566 297 502 447 441 +6.8%
Balance, $m
Balance, $m Working capital 729 1,323 1,183 619 1,052 592 1,419 1,068 918 1,483 1,075 +8.2%
Net debt 540 744 678 840 1,208 876 443 452 239 556 850 +0.3%
Shareholders’ equity 2,607 2,541 2,635 2,537 2,798 3,097 3,467 3,808 3,567 3,778 3,358 +4.2%
Returns, %
Returns, % ROA 1.89 0.86 3.53 (0.75) 6.47 8.53 6.81 5.50 1.42 7.10 6.99 +5.2 pt
ROIC 1.96 2.92 5.03 (0.48) 6.03 9.91 8.50 6.01 1.60 6.72 6.62 +4.8 pt
ROE 3.11 1.57 7.36 (1.60) 13.47 17.39 12.90 9.38 2.27 11.57 11.93 +8.5 pt
People
People Employees 4,684 4,688 4,952 5,096 5,610 6,000 6,178 5,967 5,765 5,654 — +2.1%
Revenue/emp, $m 0.29 0.30 0.30 0.30 0.33 0.38 0.35 0.33 0.34 0.37 — +2.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

QIAGEN N.V. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GH Guardant Health, Inc. $20.6B — (loss-making) — (loss-making) +36.12% (above 0%: growing) n/m +18.74% (above 0%: growing) 65.42% (36.78%) Compare
MEDP Medpace Holdings, Inc. $17.8B 34.6× 35.8× +8.50% (above 0%: growing) +24.56% (above 0%: growing) −16.59% (below 0%: shrinking) 71.39% 23.12% Compare
RVTY Revvity Inc. $16.8B 71.9× 66.2× +4.29% (above 0%: growing) +2.17% (above 0%: growing) +26.97% (above 0%: growing) 57.43% 13.05% Compare
ICLR ICON PLC $15.1B 34.5× 34.6× −2.86% (below 0%: shrinking) n/m −8.01% (below 0%: shrinking) 24.29% 9.82% Compare
CRL Charles River Laboratories International, Inc. $14.9B 300× 89.2× −2.20% (below 0%: shrinking) +530.30% (above 0%: growing) +16.29% (above 0%: growing) 36.42% 20.62% Compare
QGEN QIAGEN N.V. $10.5B 26.1× 26.0× +0.28% (above 0%: growing) +7.94% (above 0%: growing) +30.45% (above 0%: growing) 63.62% 24.75%
RDNT RadNet, Inc. $6.1B — (loss-making) 1,050× +24.99% (above 0%: growing) −47.37% (below 0%: shrinking) −43.22% (below 0%: shrinking) 14.14% 6.34% Compare
GRAL GRAIL, Inc. $5.3B — (loss-making) — (loss-making) +3.71% (above 0%: growing) n/m −24.90% (below 0%: shrinking) 0.00% (385.29%) Compare
BLLN BillionToOne, Inc. $5.3B 88.7× 146× +47.24% (above 0%: growing) +164.29% (above 0%: growing) +9.25% (above 0%: growing) 70.86% 8.96% Compare
Median of peers $15.0B 71.9× 77.7× +6.40% +24.56% +0.62% 46.93% 9.39%

All 49 Diagnostics & Research stocks →

QIAGEN N.V. (QGEN) Latest News

4 Nov

Impact 3 · · Business Wire

31 Oct

Impact 4 · · Simply Wall St.

29 Oct

Impact 4 · · Business Wire
Impact 4 · · Business Wire

28 Oct

Impact 3 · · Zacks

23 Oct

Impact 4 · · medtechdive.com

21 Oct

Impact 4 · · PR Newswire
Impact 4 · · Business Wire
Impact 4 · · Business Wire

20 Oct

Impact 4 · · Investing.com
Impact 3 · · Simply Wall St.

13 Oct

Impact 3 · · Business Wire

6 Oct

Impact 4 · · Business Wire

2 Oct

Impact 4 · · Zacks

28 Sep

Impact 4 · · Simply Wall St.
Impact 4 ·
Impact 4 · · Business Wire

24 Sep

Impact 4 · · Business Wire
Impact 3 ·

17 Sep

Impact 4 · · InvestorsHub
Impact 3 ·

5 Sep

Impact 4 ·
Impact 3 ·

28 Aug

Impact 4 ·

27 Aug

Impact 3 ·

25 Aug

Impact 3 · · medtechdive.com

24 Aug

Impact 4 ·
Impact 4 ·

14 Aug

Impact 4 ·

13 Aug

Impact 3 ·

QGEN metrics, ten years each

stockrow.com/QGEN · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com